Natera Announces the Validation and Launch of the Prospera™ Heart Transplant Assessment Test
Prospera Heart identifies rejection with exceptional performance from a single test, eliminating the need to combine two tests for each patient
AUSTIN, Texas, Aug. 31, 2021 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA) testing, today announced the validation and clinical availability of its Prospera Heart transplant assessment test for heart transplant recipients. This launch represents the first major application of the Prospera technology beyond kidney transplant and leverages Natera’s expertise from performing greater than 3 million cfDNA tests worldwide.
Prospera Heart delivers excellent performance with an area under the curve (AUC) of 0.844 from a single non-invasive test1, eliminating the need to combine two tests for each patient and thus reducing the cost to the health care system. Prospera Heart is easy to use – it does not require spinning down or shipment on dry ice.
Natera validated the Prospera test in partnership with the University of Utah and University of California, San Diego. This study of >350 biopsy-matched samples is currently in submission to a major scientific journal. "We have shown a very strong correlation between acute rejection and the Prospera Heart test in heart transplant recipients and are anticipating that the data will be published very soon," said corresponding author, Josef Stehlik, M.D., M.P.H., the Christi T Smith professor of medicine at the University of Utah School of Medicine and medical director of the heart transplant program and co-chief of the advanced heart failure program at the University of Utah Hospital.
In addition to the multi-site validation study, Natera is pleased to announce that Prospera Heart will be the donor-derived cfDNA (dd-cfDNA) test used in the landmark NIH-funded DTRT study – which is now fully enrolled. DTRT is a prospective, multi-center study that includes over 2,000 dd-cfDNA timepoints from roughly 175 heart transplant recipients who were followed for up to two years post-transplant. Natera expects the study to report results in early 2022.
Natera is also pleased to announce its sponsorship of the definitive DETECT randomized controlled trial, led by Josef Stehlik, M.D., M.P.H. and Palak Shah, M.D., M.S., heart failure/transplant specialist at the Inova Heart and Vascular Institute and director of the Inova Cardiovascular Genomics Center, which will prospectively enroll 600 patients and monitor them for one year. The goal of the study is to demonstrate that rejection surveillance of heart transplant recipients with Prospera Heart is non-inferior to rejection surveillance with endomyocardial biopsy (EMB) histology in the first year post-transplant. If successful, DETECT may allow physicians to replace surveillance biopsy, the prevailing form of monitoring used today, with dd-cfDNA testing, which would significantly expand the number of patients who could be helped with the Prospera Heart technology.
"We’re excited to validate and launch Prospera Heart to help the many patients who’ve previously had a heart transplant. Our high accuracy, strong validation results and simple logistics will make Prospera Heart very competitive. By achieving an AUC of 0.844 from a single test, we avoid the additional cost and complexity of combining two tests on the same patient," said Bernie Tobin, general manager of Natera’s organ health division. "We plan to compete hard in the current non-invasive heart transplant assessment market, and potentially expand and improve on the current standard of care through the DETECT randomized controlled trial."
About the Prospera test
The Prospera test leverages Natera’s core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of donor-derived cell-free DNA (dd-cfDNA) in the recipient’s blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy. The Prospera test has been clinically and analytically validated for performance regardless of donor relatedness, rejection type, and clinical presentation. It has been developed and its performance characteristics determined by Natera, the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.
Natera is a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical or other studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350
Media: Kate Stabrawa, Communications, Natera, Inc., 720-318-4080 firstname.lastname@example.org
- Natera clinical validation data. Manuscript on file.
SOURCE Natera, Inc.